{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:21:32Z","timestamp":1777098092126,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10067-021-05957-4","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T14:02:46Z","timestamp":1637416966000},"page":"471-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"U.","family":"Kiltz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Keininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Holdsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"issue":"10089","key":"5957_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet (London, England) 390(10089):73\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(16)31591-4","journal-title":"Lancet (London, England)"},{"key":"5957_CR2","doi-asserted-by":"publisher","unstructured":"Sieper J, Braun J, Dougados M, Baeten D (2015) Axial spondyloarthritis. Nature reviews Disease primers 1:15013. https:\/\/doi.org\/10.1038\/nrdp.2015.13","DOI":"10.1038\/nrdp.2015.13"},{"issue":"4","key":"5957_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.20990","volume":"52","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 52(4):1000\u20131008. https:\/\/doi.org\/10.1002\/art.20990","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5957_CR4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/acr.23534","volume":"70","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Heijde DV, Karki C, Palmer JB, Liu M, Pandurengan R, Park Y, Greenberg JD (2018) Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-Based Corrona Registry. Arthritis Care Res 70(11):1661\u20131670. https:\/\/doi.org\/10.1002\/acr.23534","journal-title":"Arthritis Care Res"},{"issue":"7","key":"5957_CR5","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/art.39612","volume":"68","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Mease PJ, Reveille JD, Curtis JR, Chen S, Malhotra K, Pangan AL (2016) Frequency of axial spondyloarthritis diagnosis among patients seen by US rheumatologists for evaluation of chronic back pain. Arthritis & rheumatology (Hoboken, NJ) 68(7):1669\u20131676. https:\/\/doi.org\/10.1002\/art.39612","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"5957_CR6","doi-asserted-by":"publisher","unstructured":"Poddubnyy D (2013) Axial spondyloarthritis: is there a treatment of choice? Therapeutic advances in musculoskeletal disease 5(1):45-54. https:\/\/doi.org\/10.1177\/1759720X12468658","DOI":"10.1177\/1759720X12468658"},{"issue":"6","key":"5957_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, G\u00e9her P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Comp\u00e0n V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5957_CR8","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"Davis JC, Jr., Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study G","year":"2003","unstructured":"Davis JC, Jr., Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study G (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230\u20133236. https:\/\/doi.org\/10.1002\/art.11325","journal-title":"Arthritis Rheum"},{"issue":"2","key":"5957_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study G","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study G (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582\u2013591. https:\/\/doi.org\/10.1002\/art.20852","journal-title":"Arthritis Rheum"},{"key":"5957_CR10","doi-asserted-by":"publisher","unstructured":"van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC, Jr., Group AS (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Annals of the rheumatic diseases 68 (6):922-929. https:\/\/doi.org\/10.1136\/ard.2007.087270","DOI":"10.1136\/ard.2007.087270"},{"issue":"10","key":"5957_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L (2019) 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis & rheumatology (Hoboken, NJ) 71(10):1599\u20131613. https:\/\/doi.org\/10.1002\/art.41042","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"5957_CR12","unstructured":"Brahe CH, \u00d8rnbjerg LM, Askling J, Ciurea A, Kristianslund EK, Onen F, Nordstr\u00f6m D, Santos MJ CC, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Kvien T, Birlik M, Trokovic N, Barcelos A, Ionescu R, Tom\u0161i\u010d M, Geirsson AJ, Loft AG, Mann HF, Rusman T, Gomez-Reino JJ, Jones GT, Iannone F, Pavelka K, van der Horst-Bruinsma I, Hyldstrup L, Krogh NS, Hetland ML, \u00d8stergaard M. (2018) Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice\u2013 pooled data from the Eurospa Research Network Collaboration. Arthritis & rheumatology (Hoboken, NJ) 70 (suppl 10)."},{"issue":"9","key":"5957_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R (2019) The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 78(9):1167\u20131178. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215356","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"5957_CR14","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, Group MS, Group MS (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"issue":"6","key":"5957_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, group Ms, (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070\u20131077. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209730","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5957_CR16","first-page":"260","volume":"37","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK, group Ms, (2019) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. Clin Exp Rheumatol 37(2):260\u2013269","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"5957_CR17","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","volume":"2","author":"H Marzo-Ortega","year":"2020","unstructured":"Marzo-Ortega H, Sieper J, Kivitz AJ, Blanco R, Cohen M, Pavelka K, Delicha EM, Stefanska A, Richards HB, Rohrer S (2020) 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol 2(6):e339\u2013e346. https:\/\/doi.org\/10.1016\/S2665-9913(20)30066-7","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"5957_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001005","volume":"5","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A (2019) Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 5(2):e001005. https:\/\/doi.org\/10.1136\/rmdopen-2019-001005","journal-title":"RMD Open"},{"issue":"1","key":"5957_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2020-eular.598","volume":"79","author":"J Braun","year":"2020","unstructured":"Braun J, Blanco R, Dokoupilova E, Gensler LS, Kivitz A, Hall S, Kameda H, Poddubnyy D, Van de Sande M, Van der Heijde D, Wiksten A, Porter B, Richards H, Haemmerle S, Deodhar A (2020) OP0106 Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase iii PREVENT study. Ann Rheum Dis 79(1):69\u201370. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.598","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5957_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T (2019) Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 21(1):111. https:\/\/doi.org\/10.1186\/s13075-019-1882-2","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"5957_CR21","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J (2008) Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin 24(11):3063\u20133072. https:\/\/doi.org\/10.1185\/03007990802457040","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"5957_CR22","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"key":"5957_CR23","doi-asserted-by":"publisher","unstructured":"van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Annals of the rheumatic diseases 49 (11):916-920. https:\/\/doi.org\/10.1136\/ard.49.11.916","DOI":"10.1136\/ard.49.11.916"},{"issue":"11","key":"5957_CR24","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095\u20131108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002","journal-title":"Med Care"},{"issue":"3","key":"5957_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"issue":"5","key":"5957_CR26","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","volume":"74","author":"U Kiltz","year":"2015","unstructured":"Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74(5):830\u2013835. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203967","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5957_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"5957_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"Public Policy Committee ISoP","year":"2016","unstructured":"Public Policy Committee ISoP (2016) Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 25(1):2\u201310. https:\/\/doi.org\/10.1002\/pds.3891","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"5957_CR29","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, initiative S, (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147(8):W163-194. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010-w1","journal-title":"Ann Intern Med"},{"issue":"2","key":"5957_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10067-008-1019-5","volume":"28","author":"R Ariza-Ariza","year":"2009","unstructured":"Ariza-Ariza R, Hernandez-Cruz B, Lopez-Antequera G, Navarro-Sarabia F (2009) Variables related to utility in patients with ankylosing spondylitis. Clin Rheumatol 28(2):207\u2013211. https:\/\/doi.org\/10.1007\/s10067-008-1019-5","journal-title":"Clin Rheumatol"},{"issue":"4","key":"5957_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/1573397115666191018162606","volume":"16","author":"G Elolemy","year":"2020","unstructured":"Elolemy G, Aboughanima A, Ganeb S, Elziat H (2020) Health-related quality of life in patients with ankylosing spondylitis: relationship with disease-related variables. Curr Rheumatol Rev 16(4):311\u2013318. https:\/\/doi.org\/10.2174\/1573397115666191018162606","journal-title":"Curr Rheumatol Rev"},{"issue":"Suppl 2","key":"5957_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2019-eular.437","volume":"78","author":"U Kiltz","year":"2019","unstructured":"Kiltz U, Peterlik D, Winkelmann V, Tony H-P (2019) FRI0406 AQUILA study in Germany - Real world data on secukinumab\u2019s effectiveness in ankylosing spondylitis patients - results from an interim analysis. Ann Rheum Dis 78(Suppl 2):890\u2013890. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.437","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"5957_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/annrheumdis-2019-eular.1601","volume":"78","author":"B Michelsen","year":"2019","unstructured":"Michelsen B, Brahe CH, Askling J, Codreanu C, Ciurea A, Loft AG, Mann H, Pombo-Suarez M, Onen F, Sexton J, Rotar Z, Santos MJ, Eklund K, Gudbjornsson B, Iannone F, Giuseppe DD, Ionescu R, Nissen M, Pavelka K, S\u00e1nchez-Piedra C, Akar S, Kristianslund E, Tomsic M, Santos H, Trokovic N, Geirsson AJ, Favalli EG, Ivd H-B, Macfarlane G, Hyldstrup L, Krogh NS, \u01festergaard M, Hetland ML (2019) FRI0404 Pooled 6-month treatment outcomes and drug retention rates in 1556 patients with axial spondyloarthritis treated with secukinumab in routine clinical practice in 12 European countries in the EUROSPA research collaboration. Ann Rheum Dis 78(Suppl 2):888\u2013889. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.1601","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5957_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/2374373518795414","volume":"6","author":"Q Chen","year":"2019","unstructured":"Chen Q, Beal EW, Okunrintemi V, Cerier E, Paredes A, Sun S, Olsen G, Pawlik TM (2019) The association between patient satisfaction and patient-reported health outcomes. J Patient Exp 6(3):201\u2013209. https:\/\/doi.org\/10.1177\/2374373518795414","journal-title":"J Patient Exp"},{"issue":"12","key":"5957_CR35","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1245\/s10434-017-6049-2","volume":"24","author":"DR Kaye","year":"2017","unstructured":"Kaye DR, Richardson CR, Ye Z, Herrel LA, Ellimoottil C, Miller DC (2017) Association between patient satisfaction and short-term outcomes after major cancer surgery. Ann Surg Oncol 24(12):3486\u20133493. https:\/\/doi.org\/10.1245\/s10434-017-6049-2","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"5957_CR36","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/rheumatology\/kex518","volume":"57","author":"MH Derakhshan","year":"2018","unstructured":"Derakhshan MH, Pathak H, Cook D, Dickinson S, Siebert S, Gaffney K, Nass, investigators BR, (2018) Services for spondyloarthritis: a survey of patients and rheumatologists. Rheumatology (Oxford) 57(6):987\u2013996. https:\/\/doi.org\/10.1093\/rheumatology\/kex518","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5957_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40801-019-0154-4","volume":"6","author":"M Magrey","year":"2019","unstructured":"Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y (2019) A pilot study to assess the feasibility of a web-based survey to examine patient-reported symptoms and satisfaction in patients with ankylosing spondylitis receiving secukinumab. Drugs Real World Outcomes 6(2):83\u201391. https:\/\/doi.org\/10.1007\/s40801-019-0154-4","journal-title":"Drugs Real World Outcomes"},{"key":"5957_CR38","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2147\/PPA.S137052","volume":"11","author":"CM Gonzalez","year":"2017","unstructured":"Gonzalez CM, Carmona L, de Toro J, Batlle-Gualda E, Torralba AI, Arteaga MJ, Cea-Calvo L (2017) Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. Patient Prefer Adherence 11:1243\u20131252. https:\/\/doi.org\/10.2147\/PPA.S137052","journal-title":"Patient Prefer Adherence"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05957-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05957-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05957-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T06:34:44Z","timestamp":1642746884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05957-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5957"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05957-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,20]]},"assertion":[{"value":"19 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kiltz has received grant and research support and consultancy fees from AbbVie, Amgen, Biocad, Biogen, Chugai, Eli Lilly, Fresenius, Gilead, Gr\u00fcnenthal, GSK, Janssen, MSD, Novartis, Pfizer, Roche and UCB. Dr Conaghan has served as a consultant or on speaker\u2019s bureaus for AbbVie, BMS, Eli Lilly, Galapagos, Gilead, GSK, Novartis, and Pfizer. Dorothy Keininger, Niraj Modi and Haijun Tian are employees of Novartis. Elizabeth Holdsworth, Nicola Booth and Oliver Howell are employees of Adelphi Real World.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}}]}}